Valuation : GENFIT

Market Cap 69Cr 80Cr 65Cr 59Cr 110.69Cr 7.58TCr 111.05Cr 768.73Cr 297.14Cr 3.88TCr 301.01Cr 294.43Cr 12TCr P/E 2026 *
35.6x
P/E 2027 * 91.5x
Enterprise Value 64Cr 74Cr 60Cr 55Cr 102.48Cr 7.02TCr 102.81Cr 711.72Cr 275.11Cr 3.59TCr 278.69Cr 272.6Cr 11TCr EV / Sales 2026 *
6.37x
EV / Sales 2027 * 5.02x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-3.62%
Current month-3.41%
1 month-3.41%
6 months+60.00%
Current year+155.40%
1 month 13.6
Extreme 13.6
14.08
Current year 5.2
Extreme 5.205
14.34
1 year 3.19
Extreme 3.19
14.34
3 years 3.19
Extreme 3.19
14.34
5 years 3.19
Extreme 3.19
14.34
10 years 3.19
Extreme 3.19
14.34
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-3.41%-1.81% - - 80Cr
-1.16%-2.77%-1.68%+13.85% 4.89TCr
-0.40%+1.03%+418.57%+527.30% 4.5TCr
-1.42%+2.30%+42.67%+22.37% 4.41TCr
-1.22%-2.31%+4.82%+77.49% 4.07TCr
-0.96%-2.31%+15.75%+45.41% 3.35TCr
-0.21%+9.14% - - 1.78TCr
-0.35%-1.56%+21.42%+120.75% 1.65TCr
-1.54%-1.30%+12.02%+31.14% 1.47TCr
-1.65%-1.03%+75.93%+41.12% 1.38TCr
Average -1.22%+0.48%+73.69%+109.93% 3.06TCr
Weighted average by Cap. -0.95%+0.05%+89.18%+128.66%

Financials

2026 *2027 *
Net sales 10Cr 12Cr 9.42Cr 8.6Cr 16Cr 1.1TCr 16Cr 111.74Cr 43Cr 564.26Cr 44Cr 43Cr 1.8TCr 12Cr 14Cr 12Cr 11Cr 20Cr 1.36TCr 20Cr 138.33Cr 53Cr 698.57Cr 54Cr 53Cr 2.23TCr
Net income 2.29Cr 2.66Cr 2.15Cr 1.96Cr 3.67Cr 251.59Cr 3.69Cr 26Cr 9.86Cr 128.84Cr 9.99Cr 9.77Cr 410.39Cr 68L 79.07L 63.96L 58.38L 1.09Cr 75Cr 1.1Cr 7.58Cr 2.93Cr 38Cr 2.97Cr 2.9Cr 121.98Cr
Net Debt -5.11Cr -5.94Cr -4.81Cr -4.39Cr -8.21Cr -562.14Cr -8.23Cr -57Cr -22Cr -287.87Cr -22Cr -22Cr -916.95Cr -6.62Cr -7.69Cr -6.22Cr -5.68Cr -11Cr -727.7Cr -11Cr -74Cr -29Cr -372.66Cr -29Cr -28Cr -1.19TCr
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
07/26/07 13.60 -3.41% 0
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.78EUR
Average target price
15.90EUR
Spread / Average Target
+15.38%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!